Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | OXTR | P30559 | 5/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 3/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2121913 | 0.77 | PGR (0.39) | CYP2C9PGRNR3C1ARCA1 | |
| SCHEMBL2117541 | 0.75 | ACSS2 (0.40) | KCNH2CYP2C9OXTRAVPR2AVPR1A | |
| SCHEMBL1818704 | 0.69 | NPC1 (0.41) | CYP2C9 | |
| SCHEMBL2121659 | 0.69 | OXTR (0.36) | CYP2C9OXTRAVPR1APIK3CD | |
| SCHEMBL2118049 | 0.68 | ALDH1A1 (0.40) | CYP2C9LMNAPIK3CAPIK3CG | |
| SCHEMBL2116804 | 0.68 | KIT (0.46) | CYP2C9PIK3CDLMNAPIK3CAPIK3CB | |
| SCHEMBL2117776 | 0.67 | ACLY (0.38) | PGRLMNA | |
| SCHEMBL2034337 | 0.66 | CA1 (0.54) | PGRCA1CA2PIK3CDPIK3CA | |
| SCHEMBL2119447 | 0.65 | OXTR (0.37) | CYP2C9OXTRAVPR1A | |
| SCHEMBL2117835 | 0.65 | MAPT (0.39) | CYP2C9PGRPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | KCNH2 3023/4885CYP2C9 2049/4885OXTR 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.